Management of AML Beyond “3 + 7” in 2019
The therapeutic paradigm for treatment of acute myeloid leukemia (AML) is rapidly changing with the advent of a new generation of drugs targeting diverse aspects of leukemogenesis. Whereas standard treatment for AML until recently consisted of a classic chemotherapy backbone, the incorporation of no...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
SAABRON PRESS
2019-03-01
|
Series: | Clinical Hematology International |
Subjects: | |
Online Access: | https://www.atlantis-press.com/article/125905873/view |